1. Home
  2. TVRD vs OIA Comparison

TVRD vs OIA Comparison

Compare TVRD & OIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVRD
  • OIA
  • Stock Information
  • Founded
  • TVRD 2017
  • OIA 1988
  • Country
  • TVRD United States
  • OIA United States
  • Employees
  • TVRD N/A
  • OIA N/A
  • Industry
  • TVRD Biotechnology: Pharmaceutical Preparations
  • OIA Finance Companies
  • Sector
  • TVRD Health Care
  • OIA Finance
  • Exchange
  • TVRD Nasdaq
  • OIA Nasdaq
  • Market Cap
  • TVRD 246.5M
  • OIA 269.4M
  • IPO Year
  • TVRD N/A
  • OIA N/A
  • Fundamental
  • Price
  • TVRD $24.14
  • OIA $5.60
  • Analyst Decision
  • TVRD Strong Buy
  • OIA
  • Analyst Count
  • TVRD 5
  • OIA 0
  • Target Price
  • TVRD $59.20
  • OIA N/A
  • AVG Volume (30 Days)
  • TVRD 38.6K
  • OIA 97.9K
  • Earning Date
  • TVRD 08-21-2025
  • OIA 01-01-0001
  • Dividend Yield
  • TVRD N/A
  • OIA 4.88%
  • EPS Growth
  • TVRD N/A
  • OIA N/A
  • EPS
  • TVRD N/A
  • OIA N/A
  • Revenue
  • TVRD N/A
  • OIA N/A
  • Revenue This Year
  • TVRD N/A
  • OIA N/A
  • Revenue Next Year
  • TVRD N/A
  • OIA N/A
  • P/E Ratio
  • TVRD N/A
  • OIA N/A
  • Revenue Growth
  • TVRD N/A
  • OIA N/A
  • 52 Week Low
  • TVRD $8.13
  • OIA $4.93
  • 52 Week High
  • TVRD $34.31
  • OIA $6.72
  • Technical
  • Relative Strength Index (RSI)
  • TVRD N/A
  • OIA 46.55
  • Support Level
  • TVRD N/A
  • OIA $5.73
  • Resistance Level
  • TVRD N/A
  • OIA $5.65
  • Average True Range (ATR)
  • TVRD 0.00
  • OIA 0.04
  • MACD
  • TVRD 0.00
  • OIA 0.00
  • Stochastic Oscillator
  • TVRD 0.00
  • OIA 67.78

About TVRD Tvardi Therapeutics Inc. Common Stock

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

About OIA Invesco Municipal Income Opportunities Trust

Invesco Muni Income Opps Trust operates as a diversified closed-end management investment company. Its investment objective is to provide a high level of current income which is exempt from federal income tax.

Share on Social Networks: